ATE275415T1 - Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält - Google Patents

Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält

Info

Publication number
ATE275415T1
ATE275415T1 AT96923524T AT96923524T ATE275415T1 AT E275415 T1 ATE275415 T1 AT E275415T1 AT 96923524 T AT96923524 T AT 96923524T AT 96923524 T AT96923524 T AT 96923524T AT E275415 T1 ATE275415 T1 AT E275415T1
Authority
AT
Austria
Prior art keywords
mag
methods
neural
regeneration
myelin
Prior art date
Application number
AT96923524T
Other languages
English (en)
Inventor
Marie T Filbin
Original Assignee
Res Foundation Of Cuny Hunter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Foundation Of Cuny Hunter filed Critical Res Foundation Of Cuny Hunter
Application granted granted Critical
Publication of ATE275415T1 publication Critical patent/ATE275415T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96923524T 1995-06-27 1996-06-27 Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält ATE275415T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56195P 1995-06-27 1995-06-27
PCT/US1996/011058 WO1997001352A1 (en) 1995-06-27 1996-06-27 Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof

Publications (1)

Publication Number Publication Date
ATE275415T1 true ATE275415T1 (de) 2004-09-15

Family

ID=21692042

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923524T ATE275415T1 (de) 1995-06-27 1996-06-27 Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält

Country Status (8)

Country Link
US (3) US5932542A (de)
EP (1) EP0835127B1 (de)
JP (2) JP4841017B2 (de)
AT (1) ATE275415T1 (de)
AU (1) AU731044B2 (de)
CA (1) CA2225691A1 (de)
DE (1) DE69633336T2 (de)
WO (1) WO1997001352A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE275415T1 (de) * 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
WO1999020190A1 (en) * 1997-10-23 1999-04-29 President And Fellows Of Harvard College Laser inactivation of inhibitory molecules in central nervous sy stem myelin
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
AU5339699A (en) * 1998-08-06 2000-02-28 Johns Hopkins University School Of Medicine, The Compounds for altering cell surface sialic acids and methods of use therefor
DE60137414D1 (de) 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
EP1343528A2 (de) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methoden zur stimulierung der regeneration und reparatur des nervensystems durch hemmung der phosphodiesterase typ 4
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
JP2008545705A (ja) * 2005-05-25 2008-12-18 ザ・ジョンズ・ホプキンス・ユニバーシティ 軸索再生を促進する組成物及び方法
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
WO2007117440A2 (en) * 2006-03-30 2007-10-18 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
US9937242B2 (en) 2012-04-09 2018-04-10 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
WO2014194200A1 (en) 2013-05-30 2014-12-04 Creasey Graham H Topical neurological stimulation
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
US10280386B2 (en) 2015-04-03 2019-05-07 Ecolab Usa Inc. Enhanced peroxygen stability in multi-dispense TAED-containing peroxygen solid
HK1259294A1 (zh) * 2015-11-10 2019-11-29 耶鲁大学 用於治疗自身免疫疾病和癌症的组合物及方法
EP3706856A4 (de) 2017-11-07 2021-08-18 Neurostim Oab, Inc. Nicht-invasiver nervenaktivator mit adaptiver schaltung
EP4349951B1 (de) 2018-06-15 2026-03-18 Ecolab USA Inc. Verbesserte persauerstoffstabilität unter verwendung von fettsäure in einem persauerstofffeststoff enthaltenden bleichaktivator
US11458311B2 (en) 2019-06-26 2022-10-04 Neurostim Technologies Llc Non-invasive nerve activator patch with adaptive circuit
KR20220115802A (ko) 2019-12-16 2022-08-18 뉴로스팀 테크놀로지스 엘엘씨 부스트 전하 전달 기능이 있는 비침습적 신경 액티베이터

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
ATE275415T1 (de) * 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält

Also Published As

Publication number Publication date
JP4841017B2 (ja) 2011-12-21
US5932542A (en) 1999-08-03
DE69633336T2 (de) 2005-09-22
JP2009073845A (ja) 2009-04-09
AU731044B2 (en) 2001-03-22
JPH11508886A (ja) 1999-08-03
EP0835127B1 (de) 2004-09-08
DE69633336D1 (de) 2004-10-14
CA2225691A1 (en) 1997-01-16
EP0835127A1 (de) 1998-04-15
US6203792B1 (en) 2001-03-20
US6399577B1 (en) 2002-06-04
AU6401296A (en) 1997-01-30
WO1997001352A1 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
ATE275415T1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
DE69738776D1 (de) Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
WO2002045749A8 (en) Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
ATE361752T1 (de) Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
EP0616032A3 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase.
PT948604E (pt) Produtos e metodos relacionados com pyk2
DE69838882D1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE60137414D1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
ATE236156T1 (de) Pyridocarbazol derivate die einen cgmp-pde inhibilierenden effekt haben
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
AU3009089A (en) Tetrazole excitatory amino acid receptor antagonists
ATE180983T1 (de) Verfahren zum abbau von chinolonen und naphthyridonen
DE69119759D1 (de) Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
DK0435177T3 (da) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-oner samt deres anvendelse som antikonvulsive midler
ATE116851T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung in der behandlung neurodegenerativer beschwerden.
GR3015470T3 (en) Inhibitors of lysyl oxidase.
ATE194360T1 (de) Verfahren und mittel für die herstellung von bindungsproteinen für inhibitoren von plasmaproteinasen
ATE350051T1 (de) Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ATE189385T1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0835127

Country of ref document: EP

REN Ceased due to non-payment of the annual fee